Blume-Jensen Peter

Blume-Jensen Peter is listed in filings as President and CEO at Acrivon Therapeutics, Inc. Common Stock. This profile follows SEC Form 4 activity through May 26, 2026, including purchase activity. Recent filings connect the profile to Acrivon Therapeutics, Inc. Common Stock (ACRV). The current snapshot covers public activity from Aug 16, 2024 to May 26, 2026. Reported amounts are shown as $24.6K to $941. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.